Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Capital Expenditures (2023 - 2026)

Compass Therapeutics' Capital Expenditures history spans 4 years, with the latest figure at $82000.0 for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 355.56% to $82000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $89000.0, a 43.55% increase, with the full-year FY2025 number at $25000.0, down 43.18% from a year prior.
  • Capital Expenditures hit $82000.0 in Q1 2026 for Compass Therapeutics, up from $7000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for CMPX hit a ceiling of $82000.0 in Q1 2026 and a floor of $7000.0 in Q3 2025.
  • Historically, Capital Expenditures has averaged $25857.1 across 4 years, with a median of $11000.0 in 2023.
  • Biggest five-year swings in Capital Expenditures: plummeted 84.09% in 2025 and later soared 355.56% in 2026.
  • Tracing CMPX's Capital Expenditures over 4 years: stood at $9000.0 in 2023, then skyrocketed by 388.89% to $44000.0 in 2024, then plummeted by 84.09% to $7000.0 in 2025, then soared by 1071.43% to $82000.0 in 2026.
  • Business Quant data shows Capital Expenditures for CMPX at $82000.0 in Q1 2026, $7000.0 in Q3 2025, and $18000.0 in Q1 2025.